Bariatric Surgery and GLP-1 Medications for Obesity
Author Information
Author(s): Kevin Lin, Ateev Mehrotra, Thomas C. Tsai
Primary Institution: Harvard Medical School
Hypothesis
How does the increase in GLP-1 receptor agonist prescriptions affect the rates of metabolic bariatric surgery among adults without diabetes?
Conclusion
The study found a significant increase in GLP-1 RA prescriptions and a decrease in metabolic bariatric surgery rates among adults without diabetes from 2022 to 2023.
Supporting Evidence
- GLP-1 RA prescriptions increased by 105.6% from 2022 to 2023.
- Metabolic bariatric surgery rates decreased by 8.7% during the same period.
- Patients undergoing metabolic bariatric surgery were more medically complex than those prescribed GLP-1 RAs.
Takeaway
This study shows that more people are getting weight loss medications instead of surgery, which is a big change in how obesity is treated.
Methodology
A cross-sectional study using claims data from 16.8 million unique deidentified adult patients without diabetes.
Potential Biases
Potential confounding from variations in patient adherence to GLP-1 RAs.
Limitations
The study's cross-sectional nature and potential confounding factors such as patient adherence to GLP-1 RAs.
Participant Demographics
Adults without diabetes, with a focus on those prescribed GLP-1 RAs and those undergoing metabolic bariatric surgery.
Statistical Information
P-Value
<.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website